An exploratory analysis of the TROPION-Lung01 phase 3 trial revealed TROP2 expression, measured using AstraZeneca’s computational pathology platform, as a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with datopotamab deruxtecan (Dato-DXd).

In patients whose tumors showed high TROP2-QCS biomarker levels, Dato-DXd significantly improved efficacy compared to docetaxel. A greater proportion of patients with nonsquamous NSCLC had TROP2-QCS positive tumors than those with squamous NSCLC.

In the TROP2-QCS biomarker-positive group, Dato-DXd reduced the risk of disease progression or death by 43% compared to docetaxel. Notably, this improvement in efficacy was more pronounced in the subgroup of patients with nonsquamous NSCLC without actionable genomic alterations, where Dato-DXd reduced the risk by 48%.

These findings suggest that the TROP2-QCS biomarker has the potential to identify patients who are likely to benefit most from Dato-DXd therapy in advanced NSCLC. Further research is needed to validate this biomarker and determine its role in guiding treatment decisions.

Source link: http://www.businesswire.com/news/home/20240907739903/en/Novel-Computational-Pathology-Based-TROP2-Biomarker-for-Datopotamab-Deruxtecan-Was-Predictive-of-Clinical-Outcomes-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-TROPION-Lung01-Phase-3-Trial

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.